Innovative technologies in the treatment and rehabilitation of dorsalgia: current level and prospects of carboxytherapy

Low-back pain is a serious global health problem characterized by high prevalence and significant disability burden. It is recognized as one of the main causes of disability worldwide and affects people of all age groups, although some demographic groups are more vulnerable [1–3]. Low-back pain is characterized by high prevalence. For example, in 2020, approximately 619 million people suffered from lower back pain, accounting for almost 10 % of the world’s population. Forecasts show that by 2050 this number may grow to 843 million [4–6]. Chronic low-back pain is characterized by a high disability burden. In 2020, it became a significant reason of disability-adjusted life years (DALYs), while it is estimated that about 38.8 % of DALYs were associated with professional factors, smoking and a high body mass index (BMI) [4, 5]. The economic consequences are enormous, they affect people’s quality of life and cause significant increase of healthcare expenditures worldwide.The purpose of this work was to analyze the modern scientific literature on carboxytherapy to substantiate this method as an effective and safe alternative for inclusion in the programs of comprehensive treatment and rehabilitation of patients with musculoskeletal disorders suffering from pain syndrome.